Anti-KEAP1 / Kelch-like ECH-associated protein 1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. KEAP1 antibody is designed to target Kelch-like ECH-associated protein 1, a critical regulator of cellular redox balance and stress response. The KEAP1 protein functions as a substrate adaptor protein within a Cullin 3-based E3 ubiquitin ligase complex, where it plays a central role in mediating the ubiquitination and subsequent degradation of nuclear factor erythroid 2-related factor 2 (NFE2L2, also known as NRF2). Under basal conditions, KEAP1 binds NRF2 in the cytoplasm and promotes its proteasomal degradation. This ensures that NRF2 activity remains tightly controlled to prevent unnecessary transcriptional activation of antioxidant response genes. When oxidative or electrophilic stress occurs, modifications on reactive cysteine residues of KEAP1 disrupt its interaction with NRF2, allowing NRF2 to accumulate and translocate to the nucleus to activate protective transcriptional programs.The KEAP1 protein is highly conserved and contains several functional domains, including a Broad-Complex, Tramtrack, and Bric-a-brac (BTB) domain at its N-terminus, which mediates binding to Cullin 3, and multiple Kelch repeats at the C-terminus, which recognize and bind to NRF2. Structural studies have shown that mutations within these domains often impair NRF2 binding, leading to dysregulated antioxidant signaling. KEAP1 itself is encoded by the KEAP1 gene located on chromosome 19p13.2. Mutations and epigenetic changes in KEAP1 are frequently observed in various cancers, including lung adenocarcinoma, squamous cell carcinoma, and hepatocellular carcinoma. These alterations often result in constitutive NRF2 activation, which can confer growth advantages, metabolic adaptation, and chemoresistance to tumor cells.Beyond cancer, KEAP1 has been implicated in chronic diseases characterized by oxidative stress, such as chronic obstructive pulmonary disease, cardiovascular disease, and neurodegenerative disorders like Parkinson's and Alzheimer's disease. By serving as a redox sensor, KEAP1 ensures proper cellular adaptation to fluctuating environmental conditions. The study of KEAP1 and its regulatory loop with NRF2 is central to developing targeted therapeutics aimed at either inhibiting NRF2 in cancer settings or activating it in degenerative and inflammatory diseases. Research tools such as KEAP1 antibody are therefore valuable in exploring protein expression, localization, and interactions across a range of experimental systems, including western blot, immunohistochemistry, immunoprecipitation, and ELISA.In experimental models, KEAP1 levels are often analyzed to understand stress responses at the tissue level. For example, in liver samples, KEAP1 reduction is frequently correlated with increased NRF2 nuclear accumulation, providing insights into hepatoprotective pathways. Additionally, KEAP1 expression can be modulated by environmental toxins, diet, and pharmacological agents, making it a versatile biomarker in toxicology and pharmacology research. The use of reagents like this antibody, available from NSJ Bioreagents, supports cutting-edge investigations into oxidative stress biology and translational medicine.